DNA damage response in imatinib resistant chronic myeloid leukemia K562 cells

References

• Buchdunger E, Zimmermann J, Mett H, . Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56:100–104.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Cortes J. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc 2006;81:973–988.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Cortes J. Molecular biology of BCR-ABL1-positive chronic myeloid leukemia. Blood 2009;113:1619–1630.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Dreyling M; ESMO Guidelines Working Group. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl. 5):v165–v167.
   PubMed Web of Science ®Google Scholar
• Bixby D, Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 2011;25:7–22.
   PubMed Web of Science ®Google Scholar
• Ramirez P, DiPersio JF. Therapy options in imatinib failures. Oncologist 2008;13:424–434.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Berman E, Borghaei H, . Chronic myelogenous leukemia. J Natl Compr Cancer Netw 2009;7:984–1023.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Berman E, Borghaei H, . NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw 2012;10:64–110.
   PubMed Web of Science ®Google Scholar
• Deenik W, Janssen JJWM, van der Holt B, . Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia. Haematologica 2010;95:914–921.
   PubMed Web of Science ®Google Scholar
• Tipping AJ, Mahon FX, Zafirides G, . Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia 2002;16:2349–2357.
   PubMed Web of Science ®Google Scholar
• Gromicho M, Dinis J, Magalhães M, . Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP and SLC22A1. Leuk Lymphoma 2011;52: 1980–1990.
   PubMed Web of Science ®Google Scholar
• Olive PL, Banath JP. The comet assay: a method to measure DNA damage in individual cells. Nat Protocols 2006;1:23–29.
   PubMed Web of Science ®Google Scholar
• Carpenter A, Jones T, Lamprecht M, . CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol 2006;7:R100.
   PubMed Web of Science ®Google Scholar
• Lovell DP, Omori T. Statistical issues in the use of the comet assay. Mutagenesis 2008;23:171–182.
   PubMed Web of Science ®Google Scholar
• Dinis J, Gromicho M, Martins C, . Evaluation of DSBs repair in imatinib resistant cell lines. Haematologica 2009;94(Suppl. 2): Abstract 0330.
   Google Scholar
• Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999;57: 727–741.
   PubMed Web of Science ®Google Scholar
• Carvalho C, Santos RX, Cardoso S, . Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 2009;16:3267–3285.
   PubMed Web of Science ®Google Scholar
• Beretta GL, Perego P, Zunino F. Mechanisms of cellular resistance to camptothecins. Curr Med Chem 2006;13:3291–3305.
   PubMed Web of Science ®Google Scholar
• Imlay JA, Chin SM, Linn S. Toxic DNA damage by hydrogen peroxide through the Fenton reaction in vivo and in vitro. Science 1988;240:640–642.
   PubMed Web of Science ®Google Scholar
• Epe B. DNA damage profiles induced by oxidizing agents. In: Kramer K, Krayer O, Lehnartz E, ., editors. Reviews of physiology, biochemistry and pharmacology, Vol. 127. Berlin: Springer; 1996. pp 223–249.
   Google Scholar
• Slupphaug G, Kavli B, Krokan HE. The interacting pathways for prevention and repair of oxidative DNA damage. Mutat Res 2003;531: 231–251.
   PubMed Web of Science ®Google Scholar
• Wallace SS. Biological consequences of free radical-damaged DNA bases. Free Rad Biol Med 2002;33:1–14.
   PubMed Web of Science ®Google Scholar
• Hendrich B, Hardeland U, Ng H-H, . The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sites. Nature 1999;401:301–304.
   PubMed Web of Science ®Google Scholar
• Petronzelli F, Riccio A, Markham GD, . Biphasic kinetics of the human DNA repair protein MED1 (MBD4), a mismatch-specific DNA N-glycosylase. J Biol Chem 2000;275:32422–32429.
   PubMed Web of Science ®Google Scholar
• Yoon J-H, Iwai S, O’Connor TR, . Human thymine DNA glycosylase (TDG) and methyl-CpG-binding protein 4 (MBD4) excise thymine glycol (Tg) from a Tg:G mispair. Nucleic Acids Res 2003;31:5399–5404.
   PubMed Web of Science ®Google Scholar
• Cortellino S, Turner D, Masciullo V, . The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity. Proc Natl Acad Sci USA 2003;100:15071–15076.
   PubMed Web of Science ®Google Scholar
• Screaton RA, Kiessling S, Sansom OJ, . Fas-associated death domain protein interacts with methyl-CpG binding domain protein 4: a potential link between genome surveillance and apoptosis. Proc Natl Acad Sci USA 2003;100:5211–5216.
   PubMed Web of Science ®Google Scholar
• Parsons BL. MED1: a central molecule for maintenance of genome integrity and response to DNA damage. Proc Natl Acad Sci USA 2003;100:14601–14602.
   PubMed Web of Science ®Google Scholar
• Hu J, de Souza-Pinto NC, Haraguchi K, . Repair of formamidopyrimidines in DNA involves different glycosylases. J Biol Chem 2005;280:40544–40551.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Harashima H, Kamiya H. Effects of base excision repair proteins on mutagenesis by 8-oxo-7,8-dihydroguanine (8-hydroxyguanine) paired with cytosine and adenine. DNA Repair 2010;9:542–550.
   PubMed Web of Science ®Google Scholar
• Yang N, Chaudhry MA, Wallace SS. Base excision repair by hNTH1 and hOGG1: a two edged sword in the processing of DNA damage in [gamma]-irradiated human cells. DNA Repair 2006;5:43–51.
   PubMed Web of Science ®Google Scholar
• Guay D, Garand C, Reddy S, . The human endonuclease III enzyme is a relevant target to potentiate cisplatin cytotoxicity in Y-box-binding protein-1 overexpressing tumor cells. Cancer Sci 2008;99: 762–769.
   Google Scholar
• de Lavallade H, Finetti P, Carbuccia N, . A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia. Leuk Res 2010;34:254–257.
   PubMed Web of Science ®Google Scholar
• Tipping AJ, Deininger MW, Goldman JM, . Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Exp Hematol 2003;31:1073–1080.
   PubMed Web of Science ®Google Scholar
• Villuendas R, Steegmann JL, Pollan M, . Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Leukemia 2006;20:1047–1054.
   PubMed Web of Science ®Google Scholar
• Yong ASM, Melo JV. The impact of gene profiling in chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009;22:181–190.
   PubMed Web of Science ®Google Scholar
• Burguillo FJ, Martin J, Barrera I, . Meta-analysis of microarray data: the case of imatinib resistance in chronic myelogenous leukemia. Comput Biol Chem 2010;34:184–192.
   PubMed Web of Science ®Google Scholar
• Rodrigues A, Dinis J, Gromicho M, . Genomics and cancer drug resistance. Curr Pharmaceut Biotechnol 2012;13:651–673.
   PubMed Web of Science ®Google Scholar